AU2013359179B2 - Modified AXL peptides and their use in inhibition of AXL signaling in anti-metastatic therapy - Google Patents

Modified AXL peptides and their use in inhibition of AXL signaling in anti-metastatic therapy Download PDF

Info

Publication number
AU2013359179B2
AU2013359179B2 AU2013359179A AU2013359179A AU2013359179B2 AU 2013359179 B2 AU2013359179 B2 AU 2013359179B2 AU 2013359179 A AU2013359179 A AU 2013359179A AU 2013359179 A AU2013359179 A AU 2013359179A AU 2013359179 B2 AU2013359179 B2 AU 2013359179B2
Authority
AU
Australia
Prior art keywords
axl
mer
tyro3
gas6
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2013359179A
Other languages
English (en)
Other versions
AU2013359179A1 (en
Inventor
Jennifer R. Cochran
Katherine Fuh
Amato J. Giaccia
Susan Hershenson
Douglas Jones
Mihalis Kariolis
Yu MIAO
Erinn Bruno Rankin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aravive Biologics Inc
Leland Stanford Junior University
Original Assignee
Aravive Biologics Inc
Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50934967&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2013359179(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aravive Biologics Inc, Leland Stanford Junior University filed Critical Aravive Biologics Inc
Publication of AU2013359179A1 publication Critical patent/AU2013359179A1/en
Assigned to THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY, ARAVIVE BIOLOGICS, INC. reassignment THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY Alteration of Name(s) of Applicant(s) under S113 Assignors: RUGA CORPORATION, THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
Application granted granted Critical
Publication of AU2013359179B2 publication Critical patent/AU2013359179B2/en
Priority to AU2017272193A priority Critical patent/AU2017272193A1/en
Priority to AU2019210662A priority patent/AU2019210662B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/10—Protein-tyrosine kinases (2.7.10)
    • C12Y207/10001—Receptor protein-tyrosine kinase (2.7.10.1)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AU2013359179A 2012-12-14 2013-12-12 Modified AXL peptides and their use in inhibition of AXL signaling in anti-metastatic therapy Ceased AU2013359179B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2017272193A AU2017272193A1 (en) 2012-12-14 2017-12-06 Modified AXL peptides and their use in inhibition of AXL signaling in anti-metastatic therapy
AU2019210662A AU2019210662B2 (en) 2012-12-14 2019-08-02 Modified AXL peptides and their use in inhibition of AXL signaling in anti-metastatic therapy

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261737276P 2012-12-14 2012-12-14
US61/737,276 2012-12-14
PCT/US2013/074786 WO2014093690A1 (en) 2012-12-14 2013-12-12 Modified axl peptides and their use in inhibition of axl signaling in anti-metastatic therapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2017272193A Division AU2017272193A1 (en) 2012-12-14 2017-12-06 Modified AXL peptides and their use in inhibition of AXL signaling in anti-metastatic therapy

Publications (2)

Publication Number Publication Date
AU2013359179A1 AU2013359179A1 (en) 2015-07-02
AU2013359179B2 true AU2013359179B2 (en) 2017-10-05

Family

ID=50934967

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2013359179A Ceased AU2013359179B2 (en) 2012-12-14 2013-12-12 Modified AXL peptides and their use in inhibition of AXL signaling in anti-metastatic therapy
AU2017272193A Abandoned AU2017272193A1 (en) 2012-12-14 2017-12-06 Modified AXL peptides and their use in inhibition of AXL signaling in anti-metastatic therapy
AU2019210662A Ceased AU2019210662B2 (en) 2012-12-14 2019-08-02 Modified AXL peptides and their use in inhibition of AXL signaling in anti-metastatic therapy

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2017272193A Abandoned AU2017272193A1 (en) 2012-12-14 2017-12-06 Modified AXL peptides and their use in inhibition of AXL signaling in anti-metastatic therapy
AU2019210662A Ceased AU2019210662B2 (en) 2012-12-14 2019-08-02 Modified AXL peptides and their use in inhibition of AXL signaling in anti-metastatic therapy

Country Status (11)

Country Link
US (3) US9822347B2 (enExample)
EP (2) EP3326622B1 (enExample)
JP (2) JP6345690B2 (enExample)
AU (3) AU2013359179B2 (enExample)
CA (1) CA2894539C (enExample)
DK (2) DK3326622T3 (enExample)
ES (2) ES2862335T3 (enExample)
FI (1) FI2931265T6 (enExample)
NO (1) NO3049208T3 (enExample)
PT (2) PT3326622T (enExample)
WO (1) WO2014093690A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9074192B2 (en) * 2010-01-22 2015-07-07 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of AXL signaling in anti-metastatic therapy
RU2556822C2 (ru) * 2010-01-22 2015-07-20 Те Борд Оф Трастиз Оф Те Лилэнд Стэнфорд Джуниор Юниверсити Ингибирование axl сигнализации в антиметастатической терапии
WO2013090776A1 (en) 2011-12-15 2013-06-20 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of axl/gas6 signaling in the treatment of disease
FI2931265T6 (fi) 2012-12-14 2023-05-23 Muokattuja axl-peptidejä ja niiden käyttö axl-viestinvälityksen estossa etäispesäkkeitä estävässä hoidossa
CA2909669C (en) 2014-10-20 2023-12-12 Ruga Corporation Antiviral activity of gas6 inhibitor
EP3233902B1 (en) * 2014-12-18 2020-09-09 Aravive Biologics, Inc. Antifibrotic activity of gas6 inhibitor
KR20200085307A (ko) * 2017-11-04 2020-07-14 아라바이브 바이올로직스, 인크. Axl 유인 수용체를 이용한 전이성 암의 치료 방법
JP2024533362A (ja) * 2021-09-11 2024-09-12 アラヴィヴ インコーポレイテッド Ａｘｌデコイ受容体を一次治療として使用する局所進行又は転移性膵臓腺がんを治療する方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010014755A1 (en) * 2008-07-29 2010-02-04 The Regents Of The University Of Colorado Methods and compounds for enhancing anti-cancer therapy
US20110014173A1 (en) * 2007-02-07 2011-01-20 The Regents Of The University Of Colorado Axl tyrosine kinase inhibitors and methods of making and using the same
WO2011091305A2 (en) * 2010-01-22 2011-07-28 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of axl signaling in anti-metastatic therapy

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
EP0394827A1 (en) 1989-04-26 1990-10-31 F. Hoffmann-La Roche Ag Chimaeric CD4-immunoglobulin polypeptides
US5538861A (en) 1994-07-29 1996-07-23 Amgen Inc. DNA encoding a stimulating factor for the axl receptor
US20030166107A1 (en) 1997-09-18 2003-09-04 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6737056B1 (en) * 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
EP1382969A1 (en) 2002-07-17 2004-01-21 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Diagnosis and prevention of cancer cell invasion
AU2003304180A1 (en) 2002-09-24 2005-01-04 Dow, Kenneth, Centocor, Inc. Growth arrest specific gene 6 peptides, antibodies, compositions, methods and uses
US20070142273A1 (en) 2003-04-18 2007-06-21 Sherif Daouti Methods and compositions targeting tyrosine kinases for the diagnosis and treatment of osteoarthritis
JP2005278631A (ja) 2004-03-04 2005-10-13 National Institute Of Advanced Industrial & Technology Ａｘｌリガンド結合領域蛋白質、その製造方法及びそれを用いたスクリーニング方法
CA2630475A1 (en) 2004-11-24 2006-06-01 The Regents Of The University Of Colorado Mer diagnostic and therapeutic agents
US7932032B2 (en) 2005-05-02 2011-04-26 Toray Industries, Inc. Method for diagnosing esophageal cancer
CN101679313A (zh) 2007-04-13 2010-03-24 休普基因公司 用于治疗癌症或过度增殖性疾病的axl激酶抑制剂
CA2692320A1 (en) 2007-07-02 2009-01-08 Wyeth Methods of treating bone disorders with modulators of axl
CA2747678A1 (en) * 2008-12-19 2010-06-24 Novartis Ag Soluble polypeptides for use in treating autoimmune and inflammatory disorders
KR20120035145A (ko) 2009-05-11 2012-04-13 우드라이 파마 게엠베하 인간화 ａｘｌ 항체
US9074192B2 (en) * 2010-01-22 2015-07-07 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of AXL signaling in anti-metastatic therapy
AU2011326164B2 (en) 2010-11-08 2016-05-05 The Board Of Trustees Of The Leland Stanford Junior University Fusion proteins comprising an engineered knottin peptide and uses thereof
WO2013090776A1 (en) * 2011-12-15 2013-06-20 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of axl/gas6 signaling in the treatment of disease
US20150315552A1 (en) 2012-12-14 2015-11-05 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of AXL Signaling in Primary Tumor Therapy
FI2931265T6 (fi) 2012-12-14 2023-05-23 Muokattuja axl-peptidejä ja niiden käyttö axl-viestinvälityksen estossa etäispesäkkeitä estävässä hoidossa
US20160266136A1 (en) * 2013-08-30 2016-09-15 The Board Of Trustees Of The Leland Stanford Junior University High-affinity binding to gas6
CA2909669C (en) * 2014-10-20 2023-12-12 Ruga Corporation Antiviral activity of gas6 inhibitor
EP3233902B1 (en) * 2014-12-18 2020-09-09 Aravive Biologics, Inc. Antifibrotic activity of gas6 inhibitor

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110014173A1 (en) * 2007-02-07 2011-01-20 The Regents Of The University Of Colorado Axl tyrosine kinase inhibitors and methods of making and using the same
WO2010014755A1 (en) * 2008-07-29 2010-02-04 The Regents Of The University Of Colorado Methods and compounds for enhancing anti-cancer therapy
WO2011091305A2 (en) * 2010-01-22 2011-07-28 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of axl signaling in anti-metastatic therapy

Also Published As

Publication number Publication date
DK2931265T3 (en) 2018-04-16
FI2931265T6 (fi) 2023-05-23
ES2665323T7 (es) 2023-06-15
EP3326622B1 (en) 2021-01-20
ES2862335T3 (es) 2021-10-07
AU2017272193A1 (en) 2017-12-21
AU2013359179A1 (en) 2015-07-02
WO2014093690A1 (en) 2014-06-19
US9822347B2 (en) 2017-11-21
DK2931265T6 (da) 2023-05-01
NO3049208T3 (enExample) 2018-04-14
CA2894539C (en) 2021-09-28
JP6832887B2 (ja) 2021-02-24
ES2665323T3 (es) 2018-04-25
CA2894539A1 (en) 2014-06-19
US20150315553A1 (en) 2015-11-05
US20180030422A1 (en) 2018-02-01
AU2019210662A1 (en) 2019-08-22
US11136563B2 (en) 2021-10-05
EP2931265A1 (en) 2015-10-21
HK1256071A1 (en) 2019-09-13
PT3326622T (pt) 2021-04-07
EP2931265A4 (en) 2016-08-31
JP2016510309A (ja) 2016-04-07
PT2931265T (pt) 2018-04-16
EP2931265B1 (en) 2018-01-31
US20220220458A1 (en) 2022-07-14
EP2931265B3 (en) 2023-04-05
EP3326622A1 (en) 2018-05-30
JP6345690B2 (ja) 2018-06-20
AU2019210662B2 (en) 2021-07-01
DK3326622T3 (da) 2021-04-06
JP2018154641A (ja) 2018-10-04

Similar Documents

Publication Publication Date Title
US20220220458A1 (en) Modified AXL Peptides and Their Use in Inhibition of AXL Signaling in Anti-Metastatic Therapy
CA2786149C (en) Inhibition of axl signaling in anti-metastatic therapy
US9879061B2 (en) Inhibition of AXL/GAS6 signaling in the treatment of liver fibrosis
US20150315552A1 (en) Inhibition of AXL Signaling in Primary Tumor Therapy
US20160266136A1 (en) High-affinity binding to gas6
HK1256071B (en) Modified axl peptides and their use in inhibition of axl signaling in anti-metastatic therapy
HK1242355A1 (en) Inhibition of axl signaling in anti-metastatic therapy

Legal Events

Date Code Title Description
HB Alteration of name in register

Owner name: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIO

Free format text: FORMER NAME(S): RUGA CORPORATION ; THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY

Owner name: ARAVIVE BIOLOGICS, INC.

Free format text: FORMER NAME(S): RUGA CORPORATION ; THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired